Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab pamirtecan - BioNTech

Next Previous
Drug Profile

Trastuzumab pamirtecan - BioNTech

Alternative Names: BNT-323; DB-1303

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duality Biologics
  • Developer BioNTech; Duality Biologics
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 positive breast cancer
  • Phase I/II Solid tumours
  • Clinical Phase Unknown Endometrial cancer

Most Recent Events

  • 23 Apr 2025 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy) in Moldova, USA (IV) (NCT06827236)
  • 23 Apr 2025 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Monotherapy) in Moldova, USA (IV) (NCT06827236)
  • 14 Feb 2025 BioNTech plans a phase I/II trial for Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) (IV, Infusion) in April 2025 (NCT06827236)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top